肿瘤微环境
癌症研究
癌相关成纤维细胞
趋化因子
细胞生物学
抑制器
细胞外基质
黑色素瘤
生物
信号转导
免疫疗法
MAPK/ERK通路
癌症免疫疗法
功能(生物学)
免疫抑制
癌症
细胞因子
四氯化碳
癌细胞
单克隆抗体
细胞信号
免疫学
转移
肿瘤进展
成纤维细胞
PI3K/AKT/mTOR通路
SOCS5型
转化生长因子β
化学
微泡
作者
Wei Ming Shi,Ping A. Xu,Qianlin Gu,Zhen Fan,Xin Liang,Yin Wang,Yuehui Zhao,Chenling Meng,Javier Leo,Justin J. Kim,Hongqi Teng,Jie Zhang,Feiyu Chen,Yang Chen,Nicholas E. Navin,Di Zhao
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-09-18
卷期号:: OF1-OF25
被引量:1
标识
DOI:10.1158/2159-8290.cd-25-1613
摘要
Abstract B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI